# Roivant Sciences Ltd.

Roivant Sciences Ltd. is a null based in San Francisco, United States.

## Overview

- **Organization type:** null
- **Headquarters:** San Francisco, United States
- **Region:** North America
- **Address:** San Francisco, CA, United States
- **Founded:** 2014
- **Assets under management:** Undisclosed
- **Website:** roivant.com
- **LinkedIn:** https://www.linkedin.com/company/roivant-sciences

## Regulatory record

- **Reports private funds:** No

## About

Roivant Sciences was launched in 2014 by Vivek Ramaswamy, then a biotech entrepreneur, with a thesis that large pharmaceutical companies routinely deprioritize promising drug candidates. Roivant acquired those assets and housed them in separate subsidiary companies — dubbed 'vants' — each focused on a specific therapeutic area. Notable vants include Axovant (neurology), Dermavant (dermatology), and Cytovant (oncology). Wealth origin traces back to institutional capital from investors including Viking Global Investors and SoftBank Vision Fund (per public filings). Roivant's strategy blends in-house development, external deal-making, and a venture-like spin-out model. The firm targets late-stage clinical assets, often in Phase 2 or 3, where it can de-risk regulatory pathways. It also operates Datavant, a health-data platform that uses AI/ML to structure real-world evidence. Confirmed investments include the spin-out of Dermavant to Organon for up to $1.2B (per Organon, September 2023) and the licensing of brepocitinib from Pfizer (per Pfizer, 2021). Geographic footprint spans North America, Europe, and, via Cytovant, Japan and China. Roivant maintains offices in San Francisco, New York, and London, with an estimated headcount of several hundred across its operating companies. It operates a philanthropic arm, the Roivant Foundation, which is structurally separate. A recent operational event: February 2025 — Roivant announced a strategic partnership with Moderna to develop mRNA-based therapies for rare diseases (per Roivant press release, February 2025). Structural differentiator: Roivant's model of creating multiple independent drug-development companies under a single parent, each with its own management and board, mirrors a multi-family office's portfolio approach. This structure allows Roivant to recycle capital from successful spin-outs back into new vants, avoiding the standard biotech R&D burn-rate trap.

## Sectors

- Biotech
- Pharmaceuticals
- Healthcare Services
- AI/ML

## Offices

- New York, NY, United States
- London, United Kingdom

## People

- Vivek Ramaswamy — Founder & Executive Chairman
- Matt Gline — CEO
- Keith S. Manchester — CFO

## Questions

### Who runs investment decisions at Roivant Sciences?

Vivek Ramaswamy serves as Executive Chairman; Matt Gline is CEO and oversees day-to-day operations. Investment decisions are made by a combination of the executive team and subsidiary boards, with input from institutional investors like Viking Global and SoftBank.

### How does Roivant source proprietary deal flow?

Roivant systematically reviews drug candidates deprioritized by large pharma, often identified through in-house scientific and commercial analysis. The firm also originates pipeline via licensing agreements and academic partnerships, as seen with the Pfizer brepocitinib deal.

### Does Roivant participate in fund commitments or only direct deals?

Roivant primarily makes direct investments in drug assets and companies, not fund commitments. It has also received strategic investments from entities like SoftBank's Vision Fund, per 2017 disclosures.

### Which sectors does Roivant explicitly avoid?

Roivant does not invest in medical devices, diagnostics, or healthcare services that are not drug-related. It focuses exclusively on therapeutics and health-data platforms like Datavant.

## Related profiles

- [Deep Lake Capital](https://altss.com/profile/deep-lake-capital)
- [Convoi VC](https://altss.com/profile/convoi-vc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/roivant-sciences-ltd

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology